Yorvipath (palopegteriparatide) — United Healthcare

Initial criteria

• Diagnosis of hypoparathyroidism
• Yorvipath is not being used to treat acute post-surgical hypoparathyroidism
• Patient has achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D (e.g., calcitriol) treatment

Reauthorization criteria

• Documentation of positive clinical response to Yorvipath therapy

Approval duration

12 months